

## Phase II Trial of Preoperative Chemoradiotherapy Followed by Surgical Resection in Patients With Superior Sulcus Non-Small-Cell Lung Cancers: Report of Japan Clinical Oncology Group Trial 9806

Hideo Kunitoh, Harubumi Kato, Masahiro Tsuboi, Taro Shibata, Hisao Asamura, Yukito Ichonose, Nobuyuki Katakami, Kanji Nagai, Tetsuya Mitsudomi, Akihide Matsumura, Ken Nakagawa, Hirohito Tada, and Nagahiro Saijo

### ABSTRACT

#### Purpose

To evaluate the safety and efficacy of preoperative chemoradiotherapy followed by surgical resection for superior sulcus tumors (SSTs).

#### Patients and Methods

Patients with pathologically documented non-small-cell lung cancer with invasion of the first rib or more superior chest wall were enrolled as eligible; those with distant metastasis, pleural dissemination, and/or mediastinal node involvement were excluded. Patients received two cycles of chemotherapy every 4 weeks as follows; mitomycin 8 mg/m<sup>2</sup> on day 1, vindesine 3 mg/m<sup>2</sup> on days 1 and 8, and cisplatin 80 mg/m<sup>2</sup> on day 1. Radiotherapy directed at the tumor and the ipsilateral supraclavicular nodes was started on day 2 of each course, at the total dose of 45 Gy in 25 fractions, with a 1-week split. Thoracotomy was undertaken 2 to 4 weeks after completion of the chemoradiotherapy. Those with unresectable disease received boost radiotherapy.

#### Results

From May 1999 to November 2002, 76 patients were enrolled, of whom 20 had T4 disease; 75 patients were fully assessable. Chemoradiotherapy was generally well tolerated. Fifty-seven patients (76%) underwent surgical resection, and pathologic complete resection was achieved in 51 patients (68%). There were 12 patients with pathologic complete response. Major postoperative morbidity, including chylothorax, empyema, pneumonitis, adult respiratory distress syndrome, and bleeding, was observed in eight patients. There were three treatment-related deaths, including two deaths owing to postsurgical complications and one death owing to sepsis during chemoradiotherapy. The disease-free and overall survival rates at 3 years were 49% and 61%, respectively; at 5 years, they were 45% and 56%, respectively.

#### Conclusion

This trimodality approach is safe and effective for the treatment of patients with SSTs.

*J Clin Oncol* 26:644-649. © 2008 by American Society of Clinical Oncology

### INTRODUCTION

Superior sulcus tumors (SSTs), involving structures at the thoracic inlet, represent a small subtype of non-small-cell lung carcinoma (NSCLC). These SSTs, first described by Henry Pancoast<sup>1,2</sup> and thus also called Pancoast tumors, have posed a challenging problem for surgeons, radiation oncologists, and medical oncologists alike, ever since they were first described.<sup>3</sup>

Preoperative radiotherapy has long been the community standard in the management of SSTs.<sup>4-17</sup> However, both the complete resection rate (approximately 50%) and long-term survival rate

(approximately 30%) have remained poor and unchanged over the last 40 years, since the first treatment strategy was reported in the 1960s. Local control has remained the main problem,<sup>15,17,18</sup> adversely affecting quality of life as well as survival of patients. Presence of mediastinal lymph node metastasis (N2 status) has been reported to be associated with a particularly poor prognosis.<sup>9,18</sup>

However, a series of clinical trials over the last two decades have shown concurrent chemoradiotherapy to be beneficial in the treatment of unresectable stage III NSCLC.<sup>19-21</sup> The addition of chemotherapy to thoracic radiotherapy seems to suppress distant micrometastases,<sup>22,23</sup> and giving

From the Department of Medical Oncology and Division of Thoracic Surgery, National Cancer Center Hospital, Department of Thoracic Surgery, Tokyo Medical University; Japan Clinical Oncology Group Data Center, Center for Cancer Control and Information Services, National Cancer Center; Department of Thoracic Surgery, Cancer Institute Hospital, Tokyo; Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka; Pulmonary Unit, Kobe City Medical Center General Hospital, Kobe; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashivazaki; Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya; Department of Surgery, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai; and Department of Thoracic Surgery, Osaka City General Hospital, Osaka, Japan.

Submitted September 1, 2007; accepted October 25, 2007.

Supported by the Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (Grants No. 115-2, 115-4, 145-2, 145-4, 175-2, and 175-5).

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL, and at the 11th World Conference on Lung Cancer, July 3-6, 2005, Barcelona, Spain.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Hideo Kunitoh, MD, Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; e-mail: hkunitoh@ncc.go.jp.

© 2008 by American Society of Clinical Oncology

0732-183X/08/2604-644/\$20.00

DOI: 10.1200/JCO.2007.14.1911

concurrent chemotherapy with radiotherapy has been shown to yield improved local control<sup>19,24</sup> with survival benefit.

Encouraged by the promising data of concurrent chemoradiotherapy for N2 NSCLC, the Southwest Oncology Group (SWOG) applied this modality as preoperative therapy for patients with SSTs (SWOG 9416, Intergroup Trial 0160), and reported favorable results.<sup>25</sup>

The Japan Clinical Oncology Group (JCOG) launched another trial of this preoperative concurrent chemoradiotherapy, or the trimodality approach, for the treatment of SSTs in 1999, before the first report of SWOG 9416 was published. Our study was initiated to evaluate the safety and efficacy of this treatment strategy in this rare subset of patients with NSCLC. As the induction treatment, we used mitomycin, vindesine, and cisplatin (MVP) combination chemotherapy, which has been demonstrated to be safe and effective for concurrent chemotherapy with thoracic radiotherapy in Japanese trials.<sup>19</sup>

## PATIENTS AND METHODS

### Eligibility Criteria

Patients with untreated histologically or cytologically documented NSCLC involving the superior sulcus with clinical stage T3 or T4 disease were eligible for entry onto this study. T4 diseases included tumor invasion to the spine (including to a transverse process of vertebra), aorta, or superior vena cava; invasion to the chest wall or subclavian vessels was included in T3 disease. Involvement of the superior sulcus was confirmed by computed tomographic (CT) or magnetic resonance imaging (MRI) evidence of tumor invasion of the first rib or more superior chest wall. Patients with pleural or pericardial dissemination, malignant effusion, and/or distant metastasis (M1) were excluded. Those with clinical N2 disease (mediastinal node involvement) were also excluded; all mediastinal nodes measuring  $\geq 1.0$  cm in size on CT images were required to be biopsied and documented to be negative for metastasis before patient enrollment. However, those with ipsilateral supraclavicular node involvement (N3) were eligible, unless it was accompanied by mediastinal node metastasis. Each patient was required to fulfill the following criteria: 15 to 74 years of age, Eastern Cooperative Oncology Group performance status of 0 to 1; adequate organ function (ie, leukocyte count  $\geq 4,000/\mu\text{L}$ , platelet count  $\geq 10^5/\mu\text{L}$ , hemoglobin  $\geq 11.0$  g/dL, serum creatinine less than 1.5 mg/dL, creatinine clearance  $\geq 60$  mL/min, serum bilirubin less than 1.5 mg/dL, serum ALT and AST less than double the upper limit of the institutional normal range, arterial partial pressure of oxygen  $\geq 70$  mmHg, and predicted postoperative forced expiratory volume in 1 second  $\geq 0.8$  L. From July 2001, when the protocol was revised after the death of a patient from septic shock during chemoradiotherapy, those patients with systemic use of corticosteroids were excluded.

Patient eligibility was confirmed by the JCOG Data Center before patient registration. This study was approved by the institutional review boards at each participating center, and written informed consent was obtained from all patients.

### Treatment Plan

**Induction chemotherapy.** Patients received two courses of MVP combination chemotherapy with a 4-week interval in between. Mitomycin was administered at 8 mg/m<sup>2</sup> on chemotherapy day 1, and vindesine was administered at 3 mg/m<sup>2</sup> on days 1 and 8; both were administered as bolus injections. Cisplatin was administered at 80 mg/m<sup>2</sup> as a 2-hour infusion on day 1, with ample hydration and antiemetic administration.

The second cycle of chemotherapy was postponed until all the severe toxicities recovered to grade 1 or 0. If the second cycle could not be started within 2 weeks of the due date, it was canceled, and the patient received only preoperative radiotherapy, if possible.

**Induction radiotherapy.** Thoracic radiotherapy was started with a linear accelerator ( $\geq 4$  MeV) on chemotherapy day 2. The first session was scheduled

to be given with the first chemotherapy cycle at 27 Gy in 15 fractions over 3 weeks. Then the second session was started after a week's interval until day 2 of the second course of chemotherapy. The second session, given with the second cycle of MVP, was administered at 18 Gy in 10 fractions over 2 weeks. The total radiation dose was thus 45 Gy in 25 fractions administered over 6 weeks, including the 1-week split, or interval, between the two sessions; this schedule, including the split, basically followed that of the original method reported by Furuse et al.<sup>19</sup> The radiation field included the primary tumor and the ipsilateral supraclavicular nodes. The mediastinal and hilar nodes were not irradiated, even in cases with hilar node involvement (clinical N1 cases).

**Surgery.** After the induction chemoradiotherapy, each case was re-evaluated to determine the clinical response and resectability. The resectability of the tumor was determined by the multimodality team of each institution, irrespective of the clinical response (tumor shrinkage). Surgical resection of the tumor was performed 2 to 4 weeks after the completion of the induction therapy. The surgical procedures undertaken included lobectomy or pneumonectomy, with systematic node dissection. Standard systematic node dissection, ND2, includes complete removal of the hilar and mediastinal nodes. Less complete dissection includes ND0 (ie, no systematic dissection with or without lymph node sampling) or ND1 (ie, hilar node dissection with or without mediastinal lymph node sampling).

**Boost therapy.** For unresected or incompletely resected cases, boost radiotherapy of 21.6 Gy in 12 fractions was given. Those who were judged to have undergone complete resection were followed up without additional therapy until clinical evidence of recurrence.

### Patient Evaluation and Follow-Up

Before enrollment onto the study, each patient underwent complete medical history taking and physical examination, blood cell count determinations, serum biochemistry testing, arterial blood gas analysis, chest x-ray, ECG, CT scan of the chest, bronchoscopy, CT scan or ultrasound of the upper abdomen, whole-brain CT or MRI, and an isotope bone scan. Chest MRI was recommended for evaluation of the local tumor status but was not mandatory. Blood cell counts, serum biochemistry testing, and chest x-ray were performed weekly during each course of chemotherapy. Chest CT was performed every 3 to 4 weeks during the induction therapy.

Chemotherapy toxicity was evaluated according to the JCOG Toxicity Criteria,<sup>26</sup> modified from the National Cancer Institute Common Toxicity Criteria version 1. Tumor responses were assessed radiographically according to the standard, two-dimensional WHO criteria<sup>27</sup> and were classified into complete response (CR), partial response, no change, progressive disease (PD), and not assessable. Response confirmation at 4 weeks or longer intervals was not necessitated. After curative resection and/or definitive boost radiotherapy, the patients were followed up with periodic re-evaluation, including with chest CT, as well as a systemic survey every 6 months for the first 3 years.

### Central Review

Radiographic reviews for eligibility of the enrolled patients and the clinical responses were performed at the time of the JCOG Lung Cancer Surgical Study Group meeting, held every 3 to 4 months. The study coordinator (H.K., a medical oncologist), the group coordinator (M.T., a surgical oncologist), and a few selected investigators of the group reviewed the radiographic films. The clinical response data presented below were all confirmed by this central review.

### Statistical Considerations

The primary end point of the study was the survival rate at 3 years. The sample size calculation was performed, as described in Appendix 1 (online only).

Secondary end points included the objective tumor response to chemotherapy, complete resection rate, and postsurgical morbidity/mortality. Both overall survival (OS) and progression-free survival (PFS) were calculated from the date of enrollment by the Kaplan-Meier method. For exploratory analysis to identify prognostic factors, the OS or PFS of subgroups was compared by two-sided log-rank tests. All analyses were performed with the SAS software version 8.2 (SAS Institute, Cary, NC).

## RESULTS

## Patient Characteristics

From May 1999 to November 2002, 76 patients from 19 institutions were enrolled onto the study. Three patients were ineligible. One patient was found to have concomitant anemia and did not receive the protocol treatment. Two others were found ineligible by the central review, after completion of the protocol therapy; the tumor was judged not to involve the first rib in one case, and in the other, a mediastinal node was judged to be enlarged on chest CT, without confirmation by mediastinoscopy. These two cases were included in the analysis. Therefore, 75 patients were analyzed to determine the toxicities, response rates, surgical and pathologic results, PFS, and OS. All 76 patients were included in the analysis of the patient characteristics, as shown in Table 1. In each of the T4 cases, the tumor was judged to have involved the spine. Nodal status was clinically determined and was pathologically confirmed in only a few cases.

## Induction Therapy Delivery and Toxicity

The study schema with the actual numbers of patients receiving the protocol therapy is shown in Appendix Figure A1 (online only).

Table 1. Patient Characteristics (n = 76)

Characteristic	No. of Patients	%
<b>Sex</b>		
Male	67	88
Female	9	12
<b>Age, years</b>		
Median		57.5
Range		34-74
<b>ECOG performance status</b>		
0	30	39
1	46	61
<b>Clinical T stage</b>		
T3	56	74
T4	20	26
<b>Clinical N stage</b>		
N0	59	78
N1	9	12
N2*	1	1
N3	7	9
<b>Smoking history</b>		
No	4	5
Yes	72	95
Median smoking history		1.5 packs for 37 years
<b>Body weight loss within 6 months</b>		
≤ 5%	61	80
5-10%	7	9
> 10%	5	7
Missing	3	4
<b>Histology</b>		
Adenocarcinoma	34	45
Squamous cell carcinoma	27	36
Others/unclassified	15	20
<b>Primary site</b>		
Right	39	51
Left	37	49

Abbreviation: ECOG, Eastern Cooperative Oncology Group.  
 \*Found ineligible by central review but included in the subsequent analyses.

The induction therapy could be completed in 71 (95%) of the 75 patients. The treatment was terminated in the remaining four patients after only one course of chemotherapy (owing to the development of adverse events in two cases, patient refusal in one case, and early toxicity-related death in one case).

Table 2 lists the major toxicities of the protocol therapy. They were mainly hematologic, and although more than 80% of the patients experienced neutropenia/leukopenia, they were generally transient and not complicated by infection/fever. Overall, toxicities were well tolerated. There was one toxic death on chemoradiotherapy day 6 as a result of severe myelosuppression and subsequent development of septic shock.

## Clinical Response to the Induction Therapy

The clinical responses of the 75 eligible patients to induction therapy were judged radiologically and confirmed by the central review. The responses were as follows: CR, 0 patients; partial response, 46 patients; no change, 22 patients; PD, five patients; not assessable, two patients. The overall response rate was 61% (95% CI, 49% to 72%).

## Surgical and Pathologic Results

Thoracotomy was performed in 57 (76%) of the 75 patients who received the induction therapy. The surgical procedures undertaken

Table 2. Major Toxicities of Induction Therapy (N = 75) and Postsurgical Complications

Toxicity or Complication	No. of Patients			
	Grade 1/2	Grade 3	Grade 4	% Grade 3/4
<b>Acute toxicity*</b>				
Leukopenia	1/11	37	26†	84
Neutropenia	3/9	26	36†	83
Anemia	19/47	5	0	7
Thrombocytopenia	14/12	9	2†	15
ALT	27/5	2	0	3
Creatinine	18/2	0	0	0
PaO <sub>2</sub>	37/6	0	0	0
Emesis	32/25	2	— (not defined)	3
Diarrhea	7/5	1	0	1
Constipation	22/3	1	0	1
Esophagitis	22/9	0	0	0
Infection	10/9	6	1†	9
Neuropathy	8/0	0	— (not defined)	0
Skin toxicity	16/2	1	0	1
Fever	25/19	1	1	3
<b>Postsurgical complications‡</b>				
ARDS	0	1	1 (grade 5)	
Empyema	0	2	0	
Cylothorax	1	1	0	
Pneumonitis	0	1	0	
<b>Late complications‡</b>				
Pneumonitis	0	1	0	
Bleeding	0	0	1 (grade 5)	

Abbreviations: PaO<sub>2</sub>, alveolar-arterial difference in partial pressure of oxygen; ARDS, adult respiratory distress syndrome.

\*During induction therapy.  
 †Includes one patient with toxic death owing to septic shock.  
 ‡Report of each complication was evaluated by National Cancer Institute Common Toxicity Criteria version 3.0.

were as follows: lobectomy, 53 patients; partial resection, three patients; exploratory thoracotomy, one patient; none of the cases required pneumonectomy. Combined resection of the chest wall was undertaken in 51 of the 57 patients. Complete mediastinal lymph node dissection (ND2) was performed in 42 patients, and the remaining 15 patients underwent less extensive dissection or sampling (ND0 or ND1).

The results of thoracotomy were as follows: gross residual tumor (R2 resection, including one with probe thoracotomy), three patients; microscopically residual tumor on pathologic review (R1 resection), three patients; complete surgical and pathologic resection (R0 resection), 51 patients. Pathologic downstaging of the tumor as compared with the clinical stage before induction therapy was achieved in 23 patients (40% of the patients who underwent surgery); this is an inherently inaccurate figure and should be interpreted as such, owing to the lack of pathologic confirmation of the c stage at presentation. Pathologic CR, with no residual viable tumor cells in the resected specimens, was achieved in 12 patients (16% of the 75 treated patients). Table 3 lists the surgical and pathologic results according to the initial clinical T factor.

The major postoperative morbidities included adult respiratory distress syndrome (ARDS) in two patients, empyema in two patients,

chylothorax in two patients, and pneumonitis in two patients. One patient died of sudden major bleeding on postoperative day 24. The bleeding was identified at autopsy as being from an intercostal artery. Another patient died of ARDS after off-protocol pneumonectomy. The patient had been judged to have PD in response to the induction therapy as a result of emergence of intrapulmonary metastases. The attending surgeon and the patient agreed to salvage surgery, and the patient developed postoperative ARDS.

Thus the total number of toxic deaths was three, including one caused by septic shock during the induction, one by delayed postoperative bleeding, and one by the development of ARDS after off-protocol, salvage surgery.

### Boost Therapy


Boost radiotherapy was given to 15 patients, including 12 of the 15 patients in whom thoracotomy was not performed after the completion of induction chemoradiotherapy. One patient received boost radiotherapy after grossly incomplete resection, and another received boost radiotherapy after gross complete resection with microscopically residual disease. In 12 of the 15 patients, boost radiotherapy was completed with a total dose of 66.6 Gy.

### PFS and OS


Figures 1 and 2 show the PFS and OS curves, updated in November 2006. Forty-one patients were alive, with a median follow-up period of 68 months. The median PFS time was 28 months. The PFS rates at 3 and 5 years were 49% and 45%, respectively. The median OS has not yet been reached. The OS at 3 and 5 years were 61% and 56%, respectively. Subset analysis (Appendix Figs A2 through A5, online only) revealed that clinical T stage was a prognostic factor (Appendix Fig A2). Patients with clinical T3 disease had better outcome than those with clinical T4 disease (the survival rates at 3 and 5 years were 69% and 61%, respectively, versus 40% and 40%, respectively; log-rank  $P = .031$ ). The clinical N stage and histologic type of the tumor did not significantly affect the OS (Appendix Figs A3 and A4) or PFS. As expected, the survival rate was good in patients in whom complete resection could be achieved, with a projected 5-year OS of 70% as compared with 24% in whom complete resection could not be

**Table 3.** Surgical and Pathologic Results According to Initial Clinical T Stage

Characteristic	c-T3	c-T4
No. of patients	55	20
No surgery performed		
No.	7	11
%	13	55
Reason for no surgery		
Protocol violation	0	1
Toxic death	0	1
Adverse event	0	1
Progressive disease	2	2
Judged unresectable	0	3
Patient refusal	5	3
Surgical procedures		
Thoracotomy		
No.	48	9
%	87	45
Pneumonectomy	0	0
Lobectomy	45	8
Probe thoracotomy	1	0
Other	2	1
With combined resection	44	7
Rib	38	6
Parietal pleura	4	1
Vertebra	3	3
Major vessel	3	0
Clavicle	1	0
Completeness of resection		
R2 operation	2	1
R1 operation	3	0
R0 operation		
No.	43	8
%	78	40
Pathologic results		
Downstaging	18	5
Pathologic complete response	9	3



**Fig 1.** Progression-free survival (PFS) of the 75 eligible patients. PFS at 3 years and 5 years was 49% (95% CI, 38% to 60%) and 45% (95% CI, 34% to 56%), respectively, with a median PFS of 27.7 months.



**Fig 2.** Overall survival (OS) of the 75 eligible patients. OS at 3 years and 5 years was 61% (95% CI, 49% to 71%) and 56% (95% CI, 44% to 66%), respectively. The median OS has not been reached.

achieved (Appendix Fig A5). The survival of the 12 patients with pathologic CR was especially favorable (Appendix Fig A6, online only).

#### Pattern of Relapse

So far, 39 patients have experienced tumor relapse. Table 4 lists the initial relapse sites, according to the curative extent of the surgical resection. For unresected or incompletely resected cases, locoregional relapse was predominant. To the contrary, for completely resected cases, relapse at distant sites was the most frequent relapse pattern, with some brain-only relapse patients.

### DISCUSSION

We conducted a multi-institutional phase II trial of a trimodality approach, namely, preoperative chemoradiotherapy followed by surgical resection, in patients with SSTs. Because of the rarity of this subtype of NSCLC, no randomized trial has been conducted previously.<sup>28</sup> Our report is the second of a large-scale, prospective trial after SWOG 9416/INT 0160 and reproduced its favorable outcomes.<sup>25</sup>

The long-term results of the SWOG 9416/INT 0160 trial were recently published.<sup>29</sup> Although the chemotherapy regimens used were different, a standard classic platinum-based combination was used in both. The preoperative radiotherapy doses were also identical (45 Gy), although a 1-week split (interval between two sessions) was included in our protocol (but not in the SWOG trial). Boost chemotherapy was planned after curative resection in the SWOG trial, but the compliance

**Table 4.** Initial Relapse Sites

Relapse Site	Patients With Complete Resection (n = 51)	Patients Without Complete Resection (n = 24)	Total (N = 75)
Locoregional* only	2	8	10
Distant only	14	6	20
Brain only	4	1	5
Both	4	5	9
Total	20	19	39

\*Locoregional = surgical margin, within radiation field, hilar lymph nodes, mediastinal lymph nodes, supraclavicular lymph nodes.

rate was poor,<sup>25</sup> as in other perioperative therapy reports; we had anticipated that the majority of the patients would not be fit enough for additional toxic therapy after a major thoracic surgery and did not include it in our protocol.

Despite these minor differences, the results of the two trials were strikingly similar (Table A1, online only). The radiologic response rate was higher, whereas the pathologic CR rate was lower in our trial, but the differences were probably not clinically relevant, considering interobserver differences in the response evaluation and the well-known discrepancy between clinical versus pathologic effects. The intensive trimodality approach was found to be feasible in both reports, with a reasonably low toxic death rate of 4%. The resection rate, which had remained unchanged at approximately 50% for almost 40 years with conventional preoperative radiotherapy, was approximately 70% in both studies. Particularly noteworthy was the reproducibility of the favorable survival data, with a 5-year OS rate of 44% in the United States trial and 56% in our trial, which were clearly superior to the historical value of 30%.<sup>3,25</sup>

A shift in the trend of clinical problems also became clear.<sup>25,28,29</sup> The relapse patterns changed from predominantly locoregional<sup>17,18</sup> to mainly distant recurrences in cases with complete resection,<sup>25,28,29</sup> and a significant number of such patients suffered from metastasis in the brain as the initial site of relapse.<sup>29</sup> To the contrary, complete resection could be achieved in less than half of the patients with c-T4 disease, and neither local control nor long-term survival was satisfactory in those in whom it could not be achieved. It seems that there might be room for improvement in radiotherapy.

Several questions remain unresolved. One is that of management of patients with mediastinal node involvement. These clinical N2 cases have been known to have the poorest prognosis<sup>9,18</sup> and were excluded from both the SWOG and JCOG trials. Although trimodality approaches have been reported in cases with clinical N2 stage NSCLC,<sup>30,31</sup> inclusion of the hilar and mediastinal nodes in the irradiation field increased the toxicity risk to an unacceptable level in our prior phase II trial (JCOG 9805).<sup>32</sup>

In addition to the unresolved questions above, our study also had a critical limitation. Although this was a prospective, large-scale, and multi-institutional trial, no definite conclusions could be obtained from the single-arm phase II study. As repeatedly pointed out, however, a phase III trial would be unrealistic due to the rarity of SSTs. Possibly, clinical questions common with other patient subsets could be tested in a phase III trial targeting a broader patient population; for example, patients with SSTs and other stage III NSCLC could be enrolled onto a phase III trial of prophylactic cranial irradiation after definitive induction therapy.<sup>33</sup>

In conclusion, we report a favorable outcome of preoperative chemoradiotherapy in patients with SSTs, confirming the results of the previous SWOG/Intergroup trial. We believe that this strategy may be acceptable as standard for the treatment of this disease and also serves as a reference for future trials.

#### AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Hideo Kunitoh, Harubumi Kato, Nagahiro Saijo  
**Financial support:** Nagahiro Saijo  
**Administrative support:** Nagahiro Saijo  
**Provision of study materials or patients:** Hideo Kunitoh, Harubumi Kato, Masahiro Tsuboi, Hisao Asamura, Yukito Ichonose, Nobuyuki

Katakami, Kanji Nagai, Tetsuya Mitsudomi, Akihide Matsumura, Ken Nakagawa, Hirohito Tada  
**Collection and assembly of data:** Masahiro Tsuboi, Taro Shibata  
**Data analysis and interpretation:** Taro Shibata  
**Manuscript writing:** Hideo Kunitoh, Taro Shibata  
**Final approval of manuscript:** Hideo Kunitoh, Harubumi Kato, Masahiro Tsuboi, Taro Shibata, Hisao Asamura, Yukito Ichonose, Nobuyuki Katakami, Kanji Nagai, Tetsuya Mitsudomi, Akihide Matsumura, Ken Nakagawa, Hirohito Tada, Nagahiro Saijo

## REFERENCES

- Pancoast HK: Importance of careful roentgen-ray investigation of apical chest tumors. *JAMA* 83: 1407-1411, 1924
- Pancoast H: Superior pulmonary sulcus tumor: Tumor characterized by pain, Horner's syndrome, destruction of bone and atrophy of hand muscles. *JAMA* 99:1391-1396, 1932
- Arcasoy SM, Jett JR: Superior pulmonary sulcus tumors and Pancoast's syndrome. *N Engl J Med* 337:1370-1376, 1997
- Shaw RR, Paulson DL, Kee JL Jr: Treatment of superior sulcus tumor by irradiation followed by resection. *Ann Surg* 154:29-40, 1961
- Paulson DL: The survival rate in superior sulcus tumors treated by presurgical irradiation. *JAMA* 196:342, 1966
- Hilans BS, Luomanen RK, Beattie EJ Jr: Integrated irradiation and surgery in the treatment of apical lung cancer. *Cancer* 27:1369-1373, 1971
- Paulson DL: Carcinomas in the superior pulmonary sulcus. *J Thorac Cardiovasc Surg* 70:1095-1104, 1975
- Davine JW, Mendenhall WM, Million RR, et al: Carcinoma of the superior pulmonary sulcus treated with surgery and/or radiation therapy. *Cancer* 57:941-943, 1986
- Anderson TM, Moy PM, Holmes EC: Factors affecting survival in superior sulcus tumors. *J Clin Oncol* 4:1598-1603, 1986
- Hilans BS, Martini N, Wong GY, et al: Treatment of superior sulcus tumor (Pancoast tumor). *Surg Clin North Am* 67:965-977, 1987
- Shahian DM, Neptune WB, Ellis FH Jr: Pancoast tumors: Improved survival with preoperative and postoperative radiotherapy. *Ann Thorac Surg* 43:32-38, 1987
- Neal CR, Amdur RJ, Mendenhall WM, et al: Pancoast tumor: Radiation therapy alone versus preoperative radiation therapy and surgery. *Int J Radiat Oncol Biol Phys* 21:651-660, 1991
- Maggi G, Casadio C, Pischedda F, et al: Combined radiosurgical treatment of Pancoast tumor. *Ann Thorac Surg* 57:198-202, 1994
- Komaki R, Roth JA, Walsh GL, et al: Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. *Int J Radiat Oncol Biol Phys* 48:347-354, 2000
- Martind E, D'Auffred A, Thomas P, et al: Management of superior sulcus tumors: Experience with 139 cases treated by surgical resection. *Ann Thorac Surg* 73:1534-1539, 2002
- Muscolino G, Valente M, Andreani S: Pancoast tumours: Clinical assessment and long-term results of combined radiosurgical treatment. *Thorax* 52:284-286, 1997
- Ginsberg RJ, Martini N, Zaman M, et al: Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. *Ann Thorac Surg* 57:1440-1445, 1994
- Rusch VW, Parekh KR, Leon L, et al: Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. *J Thorac Cardiovasc Surg* 119:1147-1153, 2000
- Furuse K, Fukuoaka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. *J Clin Oncol* 17:2692-2699, 1999
- Curran WJ Jr: Treatment of locally advanced non-small cell lung cancer: What we have and have not learned over the past decade. *Semin Oncol* 32:S2-S5, 2005
- Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. *Lung Cancer* 46:87-98, 2004
- Sause W, Kolesar P, Taylor SI, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. *Chest* 117: 358-364, 2000
- Dillman RO, Seagren SL, Probert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. *N Engl J Med* 323:940-945, 1990
- Schaake-Koning C, van den Bogaert W, Daleisio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. *N Engl J Med* 326:524-530, 1992
- Rusch VW, Giroux DJ, Kraut MJ, et al: Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *J Thorac Cardiovasc Surg* 121:472-483, 2001
- Tobinai K, Kohno A, Shimada Y, et al: Toxicity grading criteria of the Japan Clinical Oncology Group. *Jpn J Clin Oncol* 23:250-257, 1993
- Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. *Cancer* 47: 207-214, 1981
- Wright CD, Menard MT, Wain JC, et al: Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus. *Ann Thorac Surg* 73:1541-1544, 2002
- Rusch VW, Giroux D, Kraut MJ, et al: Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: Long-term results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). *J Clin Oncol* 25:313-318, 2007
- Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. *J Clin Oncol* 13:1880-1892, 1995
- Albain KS, Swann RS, Rusch VR, et al: Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). *Proc Am Soc Clin Oncol* 23:624S, 2005 (abstr 7014)
- Kunitoh H, Saijo N, Tsuboi M, et al: A pilot trial of preoperative MVP-combined chemoradiotherapy: Mitomycin C (MMC), vindesine (VDS), and cisplatin (CDDP), concurrently given with thoracic radiotherapy (TRT) in N2 non-small cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol* 19:530a, 2000 (abstr 2085)
- Stuschke M, Eberhardt W, Pottgen C, et al: Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuro-psychologic effects. *J Clin Oncol* 17:2700-2709, 1999

## Acknowledgment

We thank Mieko Imai for data management and Takashi Asakawa and Naoki Ishizuka, PhD, for statistical analyses.

## Appendix

The Appendix is included in the full-text version of this article, available online at [www.jco.org](http://www.jco.org). It is not included in the PDF version (via Adobe® Reader®).

## Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients

Kazuhiro Nakagawa<sup>1</sup>, Koichi Yamazaki<sup>2</sup>, Hideo Kunitoh<sup>3</sup>, Toyoaki Hida<sup>4</sup>, Kenichi Gemba<sup>5</sup>, Tetsu Shinkai<sup>6</sup>, Yukito Ichinose<sup>7</sup>, Susumu Adachi<sup>8</sup>, Yoshihiro Nambu<sup>9</sup>, Nagahiro Saijo<sup>10</sup> and Masahiro Fukuoka<sup>1</sup>

<sup>1</sup>Kinki University School of Medicine, Department of Medical Oncology, Osakasayama, Osaka, <sup>2</sup>Hokkaido University School of Medicine, First Department of Medicine, Sapporo, <sup>3</sup>National Cancer Center Hospital, Department of Internal Medicine and Thoracic Oncology, Tokyo, <sup>4</sup>Aichi Cancer Center Hospital, Department of Thoracic Oncology, Nagoya, <sup>5</sup>Okayama Rosai Hospital, Department of Respiratory Medicine, Okayama, <sup>6</sup>NHO Shikoku Cancer Center, Department of Medicine and Thoracic Oncology, Matsuyama, <sup>7</sup>National Kyushu Cancer Center, Department of Thoracic Oncology, Fukuoka, Japan, <sup>8</sup>Eli Lilly and company, Lilly Research Laboratories, Indianapolis, IN, USA, <sup>9</sup>Eli Lilly Japan K.K., Lilly Research Laboratories Japan, Kobe and <sup>10</sup>National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Received October 3, 2007; accepted March 1, 2008; published online April 22, 2008

**Background:** Pemetrexed in combination with cisplatin (Pem/Cis) is used globally for the treatment of malignant pleural mesothelioma (MPM). This Phase I/II study was conducted to determine the recommended dose (RD) (Phase I) of Pem/Cis, and evaluate the efficacy and safety (Phase II) in Japanese MPM patients.

**Methods:** Key eligibility criteria were histologic diagnosis of MPM incurable by surgery, no prior chemotherapy, and a performance status 0-1. Under full vitamin supplementation, pemetrexed was intravenously administered on Day 1 of a 21-day cycle, followed by cisplatin. A cohort of six patients, starting from pemetrexed 500 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup> (Level 1), were studied in the dose-escalation Phase I (Step 1). The RD determined in Step 1 was carried forward into Phase II (Step 2). Planned number of patients treated with Pem/Cis was 18-38.

**Results:** In Step 1, 13 patients were enrolled: seven in Level 1 and six in Level -1 (pemetrexed 500 mg/m<sup>2</sup>, cisplatin 60 mg/m<sup>2</sup>). Two of six evaluable patients had dose-limiting toxicities (pneumonitis and neutropenia) in Level 1, establishing Level 1 as the RD. In Step 2, 12 patients were enrolled, for a total of 19 patients treated at the RD. Seven patients achieved a partial response among these patients, for a response rate of 36.8% (95% confidence interval: 16.3-61.6); overall survival was 7.3 months. One drug-related death occurred due to worsening of a pre-existing pneumonia. Common grade 3/4 toxicities were neutropenia and decreased-hemoglobin.

**Conclusion:** The Pem/Cis combination provides promising activity and an acceptable safety profile for chemonaive Japanese MPM patients with the same recommend dosage and schedule used in rest of the world.

*Key words:* cisplatin - mesothelioma - pemetrexed - phase I/II

### INTRODUCTION

Malignant pleural mesothelioma (MPM) is a tumor derived from the mesothelium covering the surface of pleural

membranes or from undifferentiated mesenchymal cells in connective tissue under the membranes. MPM is a locally invasive and aggressive tumor with a poor prognosis and a median survival time (MST) of  $\approx$ 9-16 months (1).

MPM is known to be linked to asbestos exposure, and the incidence of this tumor is expected to increase in the next 10-20 years according to an estimation of asbestos consumption in

For reprints and all correspondence: Kazuhiro Nakagawa, Kinki University School of Medicine, Medical Oncology, 377-2 Ohnohigashi, Osakasayama 589-8511, Japan. E-mail: nakagawa@med.kindai.ac.jp

the world (9). Recently, the prevalence of MPM in Japan was widely recognized after uncovering the high incidence of MPM and MPM-related deaths in ex-workers of asbestos factories and in residents of the surrounding areas who may have been subject to non-occupational exposure to asbestos fibers.

Surgical resection offers local control of the tumor but its effect on survival remains unclear. In addition, application of radiation therapy is limited because of the diffuse extension of tumor spread. Regimens applied to lung cancer such as platinum-containing chemotherapy have been used for MPM in Japan; however, the efficacy outcomes of these therapies are not satisfactory. Therefore, effective systemic chemotherapy for MPM is clearly needed.

Pemetrexed is a novel antifolate (12) that inhibits three enzymes in folate metabolism: thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase (11). Because of the multi-targeted profile of this compound, broad and preferable anti-tumor activity is expected. Pemetrexed has shown clinical activity in various tumors including mesotheliomas (6). A pivotal multicenter, randomized Phase III study of pemetrexed (500 mg/m<sup>2</sup>) in combination with cisplatin (75 mg/m<sup>2</sup>) versus cisplatin alone (cisplatin 75 mg/m<sup>2</sup>) in patients with MPM who had no prior chemotherapy was conducted in 20 countries (not including Japan) (16). A total of 448 patients were randomized and treated in this study (226 treated by pemetrexed/cisplatin (Pem/Cis) and 222 treated by cisplatin). MST in the Pem/Cis arm was 12.1 months compared with 9.3 months in the cisplatin arm ( $P = 0.020$ , two-sided log rank test). This was the first confirmation of significant prolongation of survival for patients with MPM. On the basis of this evidence, the combination of pemetrexed and cisplatin was approved for the treatment of MPM in the USA in 2004. Since then, the combination therapy has been approved in more than 80 countries and regions for the treatment of MPM, and recognized as a standard care for MPM (8).

In 2005, we initiated a Phase I/II study of Pem/Cis therapy in Japanese patients with MPM who had no prior chemotherapy. The primary objectives of this study were to determine the clinically recommended dose (RD) of Pem/Cis therapy in the Phase I portion of the study (Step 1), and to examine tumor response of the combination therapy in the Phase II portion (Step 2). The secondary objectives included time-to-event efficacy outcomes [the duration of response, progression free survival (PFS), and overall survival time], 1-year survival rate, quality of life (QOL) assessments, pulmonary function tests and safety.

## PATIENTS AND METHODS

### PATIENT SELECTION

Chemonaive patients with histological diagnosis of MPM, regardless of clinical stage and who were not candidates for curative surgery, were assessed for eligibility. Eligible patients needed to be 20–74 years old with a life expectancy  $\geq 12$  weeks and an Eastern Cooperative Oncology Group performance status (PS) 0 or 1. Patients were also required

to have adequate organ functions: bone marrow reserve [platelets  $\geq 100 \times 10^3/\text{mm}^3$ , hemoglobin  $\geq 9.0$  g/dl, and absolute neutrophil count (ANC)  $\geq 2.0 \times 10^3/\text{mm}^3$ ], hepatic function [bilirubin  $\leq 1.5 \times$  upper limit of normal (ULN), aspartate/alanine transaminase (AST/ALT)  $\leq 2.5 \times$  ULN, and serum albumin  $\geq 2.5$  g/dl], renal function (serum creatinine  $\leq$  ULN, and calculated creatinine clearance  $\geq 45$  ml/min using the Cockcroft and Gault formula), lung function (functional oxygen saturation [ $\text{SpO}_2$ ]  $\geq 92\%$ ) and normal electrocardiogram.

Patients were excluded from this study for active infection, symptomatic brain metastasis, a wide-spread diffuse shadow in the lung caused by interstitial pneumonitis diagnosed by chest X-ray, pregnancy, serious concomitant systemic disorders incompatible with the study, clinically significant effusions, Common Terminology Criteria for Adverse Events (CTCAEs) v3 grade  $\geq 2$  peripheral neuropathy, the inability to discontinue aspirin and other non-steroidal anti-inflammatory agents or the inability or unwillingness to take folate and vitamin B<sub>12</sub> during the study.

This study was conducted in compliance with the guidelines of good clinical practice and the Declaration of Helsinki, and it was approved by the local institutional review boards. All patients gave written informed consent before study entry. The Efficacy and Safety Evaluation Committee (ESEC), an independent body, was consulted if any efficacy and safety issues arose in the study.

### STUDY DESIGN

This was a Phase I/II, multicenter, single-arm, open-label study, performed in two steps. The RD level established in Step 1 was carried forward in Step 2. Patients enrolled in Step 1 at the RD level could continue in Step 2 unless otherwise indicated. The planned number of patients in total of Steps 1 and 2 treated with Pem/Cis was 18–38 for examination of efficacy and safety profile. In Step 1, six patients were to be enrolled in each dose level. The lower number of the planned number of patients, 18, was set as the minimum number of patients needed to confirm that the response rate of the study drugs was significantly larger than the threshold rate of 10% at one-sided significant level 0.05 with  $\geq 80\%$  power.

### STUDY TREATMENT

Pemetrexed was intravenously administered as a 10-min infusion on Day 1 of a 21-day cycle, followed by cisplatin administration intravenously as a 2-h infusion 30 min after pemetrexed administration. Patients were instructed to take a daily 1 g multivitamin containing 500  $\mu\text{g}$  of folate beginning 1 week prior to Day 1 of Cycle 1 until study discontinuation. Vitamin B<sub>12</sub> (1000  $\mu\text{g}$ ) was intramuscularly injected, starting 1 week prior to Day 1 of Cycle 1 and repeated every 9 weeks until study discontinuation. Patients remained on study unless they were discontinued, for instance, due to disease progression and unacceptable adverse events.



evaluations of overall survival time and 1-year survival rate, survival surveillance period was defined as from the beginning of the study treatment to 1 year after the last patient began study treatment. Patients who received the study drugs and complied with all inclusion/exclusion criteria were included in full analysis set (FAS). Patients who were treated with the RD level in Step 1 or 2 among FAS were included in efficacy analysis set for efficacy evaluation. Patients who received the study drugs at least once were included in safety analysis set for safety evaluation.

Assessment results of the best overall response by the E-CJC were used for efficacy analysis. Statistical tests based on binominal distribution were done to confirm that the response rate of the study drugs was significantly larger than the threshold rate of 10% at one-sided significant level 0.05. The threshold rate 10% was set on the basis of historical data on the response rate of cisplatin alone arm reported in other studies (15,16).

## RESULTS

### PATIENT CHARACTERISTICS

From 2005 to 2006, a total of 25 Japanese patients with MPM were enrolled in Steps 1 and 2 at seven centers in Japan. All patients met the eligibility criteria and received study treatment; all were included in FAS. One patient was still receiving the study drug at the time of the efficacy and safety evaluations in this report.

Patient characteristics are summarized in Table 1. The majority of patients were male (22 patients, 88.0%). The median age was 61 years (range: 50–74 years). Most patients had a PS of 1 (18 patients, 72.0%) and clinical stage IV (21 patients, 84.0%). The predominant histologic subtype was epithelial in 64% of patients. Two demographic characteristics showed differences among dose levels. There were more patients with PS 0 in Level -1 (50.0%) than in Level 1 (21.1%). All six (100%) patients in Level -1 had the epithelial subtype versus 10 (52.6%) patients in Level 1.

### DOSE-ESCALATION, DOSE-LIMITING TOXICITY AND RD

One patient in Level 1 of Step 1 died on Day 14 of Cycle 1 due to exacerbation of pneumonia, respiratory failure (hypoxia) and disseminated intravascular coagulation (DIC). The ESEC evaluated the case of the early death. Since the patient had had the shadow of the lung detected by radiographic image prior to receiving study treatment, it was unlikely that the administration of pemetrexed was the primary cause of the pneumonia. The autopsy of this patient showed that interstitial changes in the lung were mild and the pathological diagnosis was an organizing pneumonia. The result of the autopsy was compatible with the clinical course and suggested that the direct cause of the death was not the drug-induced interstitial pneumonia but the exacerbation of infectious pneumonia, worsened by the study treatment. The case, therefore, was considered not appropriate for the DLT evaluation.

Table 1. Patient characteristics

	Step 1 Level -1 (n = 6)	Level 1 (n = 19)	All treated (n = 25)
Gender			
Male	5	17	22
Female	1	2	3
Age			
Mean	61	61	61
SD	3.9	6.3	5.8
Med	61	59	61
Weight(kg)			
Mean	62.8	58.1	59.2
SD	8.51	11.19	10.65
Performance status prior to Cycle 1			
0	3	4	7
1	3	15	18
Histological subtype			
Epithelioid mesothelioma	6	10	16
Sarcomatoid mesothelioma	0	5	5
Biphasic mesothelioma	0	4	4
Other	0	0	0
Asbestos exposure			
Had no exposure	2	3	5
Had exposure	4	16	20
Stage of disease			
Ia	0	0	0
Ib	0	1	1
II	0	1	1
III	1	1	2
IV	5	16	21

Level 1: pemetrexed 500 mg/m<sup>2</sup> + cisplatin 75 mg/m<sup>2</sup>  
 Level -1: pemetrexed 500 mg/m<sup>2</sup> + cisplatin 60 mg/m<sup>2</sup>  
 SD, standard deviation.

One patient was added in this dose level to assess the safety profile additionally. Among the six patients in Level 1 excluding the case inappropriate for the DLT evaluation, two patients showed DLTs: drug-induced pneumonitis in one patient and dose delay of Cycle 2 initiation due to decreased neutrophil count in the other. According to the protocol definition, Level 1 was determined to be an RD for the next phase (Fig. 1).

The ESEC, however, recommended examining the treatment at Level -1 (pemetrexed 500 mg/m<sup>2</sup> and cisplatin 60 mg/m<sup>2</sup>) exploratively to accumulate more safety information. Accordingly, six patients were enrolled and treated at Level -1, and no DLTs were observed in this dose level.

Evaluating the data of these two levels together, the ESEC agreed to continue Step 2 carefully with the dose of Level 1. The sponsor decided to carry forward into Step 2 with

an RD of Level 1 (pemetrexed 500 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup>). In Step 2, 12 patients were treated at Level 1.

#### EFFICACY

Nineteen patients (7 in Step 1 and 12 in Step 2) in Level 1 were included in the efficacy analysis set and of 19 patients, seven patients had PR, five patients had stable disease (SD), six patients had PD and one patient was classified as not evaluated. An overall response rate (ORR) was 36.8% [95% confidence interval (CI): 16.3%–61.6%]. The 95% one-sided confidence lower limit was 18.8%, exceeding the threshold level of 10%. The six patients in Level -1 had PR; thus, the ORR for all 25 patients treated with the study drug reached 52.0% (13 total PR, 95% CI: 31.3%–72.2%).

The secondary efficacy variables were time-to-event outcomes (the duration of response, PFS and overall survival time), 1-year survival rate, QOL and pulmonary function test. The median duration of response was 5.2 months (95% CI: 4.3–7.3 months) for the seven responders in the efficacy analysis set (Table 2). The median duration of response for the six responders at Level -1 was again 5.2 months. For the efficacy analysis set, median PFS was 4.7 months (95% CI: 1.3–6.5 months) and MST was 7.3 months (95% CI: 4.6–14.2 months, Fig. 2) with 1-year survival rate of 36.8% (95% CI: 15.2%–58.5%). Median PFS for the six patients at Level -1 was 10.1 months. MST at Level -1 could not be calculated by Kaplan–Meier method. The 1-year survival rate of Level -1 (66.7%) was beyond 50%.

The QOL-ACD and FACT-L measures were used for QOL evaluation. There were no major changes from prior to Cycle 1 to 3 months after Cycle 1 treatment in the mean scores for the activity and physical condition subscales of QOL-ACD (Table 3); however, mean scores from prior to Cycle 1 to 3 months after Cycle 1 treatment for the psychological condition and social relationships subscales numerically increased. The mean LCS score of FACT-L did not change substantially from prior to Cycle 1 to 3 months after Cycle 1 treatment (data not shown). These score changes indicate that QOL of the patients was maintained without worsening from baseline. Pulmonary function was also maintained with no worsening from baseline observed in the pulmonary function tests (FEV<sub>1</sub>, FVC and VC) in the efficacy analysis set (data not shown).

#### SAFETY

Of 25 patients of the safety analysis set, three died during the study period: one (Level 1, Step 1) from exacerbation of pneumonia as a pre-existing complication, respiratory failure, and DIC, as described earlier, and the other two (Step 2) due to study disease. Two patients experienced non-fatal serious adverse events (fever and aspiration pneumonia, respectively). A causal relationship between fever and the study drugs could not be ruled out, but the aspiration pneumonia was not considered related to study drugs. Adverse events leading to discontinuation from study treatment were observed in six patients: one patient at Level 1 and three patients at Level -1 in Step 1 and in two patients in Step

Table 2. Summary of time-to-event outcomes and 1-year survival rates

	Step 1 Level -1 (n = 6)	Level 1 (n = 19)	All treated (n = 25)
Duration of response (months)			
Responders	6	7	13
Med	5.2	5.2	5.2
(95% CI)	3.1 – *	4.3–7.3	4.3–7.3
Range	2.7–9.6	2.0–7.3	2.0–9.6
Censored (%)	50	14.3	30.8
Progression free survival (months)			
Med	10.1	4.7	4.8
(95% CI)	4.3 – *	1.3–6.5	2.5–7.1
Range	3.3–12.1	0.5–9.6	0.5–12.1
Censored (%)	50	10.5	20
Overall survival (months)			
Med	NA	7.3	9.2
(95% CI)	11.1 – *	4.6–14.2	5.8–14.4
Range	8.6–19.3	0.5–21.5	0.5–21.5
Censored (%)	66.7	21.1	32
1-year survival rate (%)			
	66.7	36.8	44.0
(95% CI)	28.9–100.0	15.2–58.5	24.5–63.5

\*Not calculated. NA, not assessed.

Level 1: pemetrexed 500 mg/m<sup>2</sup> + cisplatin 75 mg/m<sup>2</sup>.

Level -1: pemetrexed 500 mg/m<sup>2</sup> + cisplatin 60 mg/m<sup>2</sup>.

CI, confidence interval.

2. Adverse event leading to discontinuation in two or more patients was increased blood creatinine (two patients).

Grade 3 or more laboratory TEAEs were observed in 16 patients: four patients at Level 1 and five patients at Level -1 in Step 1 and in seven patients in Step 2. Laboratory TEAEs observed in at least half of the 25 patients were decreased-hemoglobin, decreased red blood cell count, decreased neutrophil count, decreased white blood cell count, decreased lymphocyte count, increased blood urea and decreased body weight (Table 4). Grade 3 or more non-laboratory TEAEs were observed in eight patients: three patients at Level 1 and one patient at Level -1 in Step 1 and in four patients in Step 2. Non-laboratory TEAEs observed in at least half of the 25 patients were nausea, anorexia, vomiting and malaise. No major differences between Levels 1 and -1 (Step 1) in the incidence of TEAEs were noted.

For the 19 patients at Level 1, laboratory TEAEs of grade 3 or higher, possibly related to drug, and observed in at least two patients were decreased neutrophil count (seven patients, 36.8%), decreased hemoglobin (six patients, 31.6%), decreased white blood cell count (five patients, 26.3%), decreased lymphocyte count (five patients, 26.3%),




Figure 2. Kaplan-Meier plot of overall survival in the efficacy analysis set. Solid lines, overall survival; dotted lines, high and low limits of 95% confidence interval.

decreased platelet count (two patients, 10.5%) and decreased blood potassium (two patients, 10.5%). Non-laboratory adverse drug reactions of grade 3 or higher observed in at least two patients were vomiting (three patients, 15.8%), anorexia (three patients, 15.8%), nausea (two patients, 10.5%) and malaise (two patients, 10.5%). Adverse drug reactions of grade 3 or higher for the six patients in Level -1 were decreased neutrophil count (three patients), decreased-hemoglobin (two patients), decreased lymphocyte count (two patients) and decreased red blood cell count (one patient).

## DISCUSSION

This Phase I/II study reports the first experience of the combination of pemetrexed and cisplatin therapy in Japanese patients. The RD of Pem/Cis combination therapy was established at pemetrexed 500 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup>, with pemetrexed administration on Day 1 of each 21-day cycle followed by cisplatin, which is the same regimen used in worldwide for patients with MPM (16).

Of the 19 patients evaluable for efficacy at the RD level, there were PRs in seven patients, for an ORR of 36.8% (95% CI: 16.3%–61.6%). A pivotal Phase III study of the same regimen as that applied of the present study, yielded a response rate of 41.3% (95% CI: 34.8%–48.1%) in 225 patients (16). The response rates from both studies are comparable despite of the large difference in sample size.

The response rate of all the 25 treated patients was higher than the response rate for the 19 patients treated at the RD (52.0% versus 36.8%). This is due to the fact that all the six patients in Level -1 had PR. The excellent outcome observed in Level -1 may be attributed to differences

between those patients who received the RD and those patients in Level -1 in the histological subtype of mesothelioma. All six patients in Level -1 had an epithelial subtype, which is known as a favorable prognostic factor, while only about half of the 19 patients at the RD had this subtype. In addition, the PS of the patients in Level -1 was better than the patients at RD.

A secondary efficacy endpoint MST showed 7.3 months in this study, shorter than that of the Pem/Cis arm in the Phase III study (12.1 months) (16). Although it would be difficult to compare MST of this study derived from a small sample size with the large Phase III study ( $n = 226$ ), the discrepancy of survival between the two studies could be ascribed for the demographic characteristics of patients in both. There are less patients who had good prognostic factors in this study than in the Pem/Cis arm of the Phase III study: epithelial subtype: 52.6% versus 68.1%, a good PS: 21.1% (PS = 0) versus 51.8% (Karnofsky PS = 90/100) and clinical stage I/II: 8.0% versus 22.6% (16).

In this study, the most common adverse events (>50% of patients) were decreased-hemoglobin, erythropenia, neutropenia, leukopenia and lymphopenia for laboratory parameters, and nausea, anorexia, and vomiting for non-laboratory parameters. These hematologic and gastrointestinal events were similarly observed in the Pem/Cis arm of the pivotal Phase III study (16). No grade 3/4 febrile neutropenia toxicity which is a potentially life-threatening event was reported in our study. One death by pneumonitis was observed in this study; however, the patient was considered to have a pre-existing condition before initial treatment with study therapy. Adverse events observed in this study were predictable from safety profile observed in overseas trials and market experiences of pemetrexed and cisplatin combination therapy.

**Table 3.** Summary of QOL questionnaire for cancer patients treated with anticancer drugs (Level 1, n = 19)

Subscale	Measurement Point	n	Mean	SD	Min	Med	Max
<b>Activity</b>							
	Prior to Cycle1	19	62.9	25.35	20.0	60.0	100.0
	Prior to Cycle2	15	61.8	32.27	5.0	70.0	100.0
	Prior to Cycle3	14	69.6	21.79	20.0	75.0	95.0
	Cycle1 + 3M	11	60.5	32.13	5.0	70.0	100.0
<b>Physical</b>							
	Prior to Cycle1	19	64.7	22.33	15.0	70.0	100.0
	Prior to Cycle2	15	64.3	18.11	20.0	65.0	95.0
	Prior to Cycle3	14	66.2	18.33	30.0	70.0	85.0
	Cycle1 + 3M	11	61.4	21.46	35.0	60.0	95.0
<b>Psychological</b>							
	Prior to Cycle1	19	53.2	20.62	12.5	56.3	81.3
	Prior to Cycle2	15	59.6	24.87	12.5	62.5	100.0
	Prior to Cycle3	14	58.0	17.41	31.3	56.3	87.5
	Cycle1 + 3M	11	61.4	18.07	37.5	68.8	87.5
<b>Social</b>							
	Prior to Cycle1	19	32.9	21.56	5.0	25.0	75.0
	Prior to Cycle2	15	33.7	19.13	0.0	25.0	70.0
	Prior to Cycle3	14	43.6	19.94	10.0	42.5	85.0
	Cycle1 + 3M	11	36.4	22.59	10.0	30.0	85.0
<b>Face scale</b>							
	Prior to Cycle1	19	50.0	23.57	0.0	50.0	100.0
	Prior to Cycle2	14	55.4	24.37	0.0	50.0	100.0
	Prior to Cycle3	14	64.3	23.44	25.0	50.0	100.0
	Cycle1 + 3M	11	63.6	20.50	25.0	75.0	100.0

Level 1: pemtrexed 500 mg/m<sup>2</sup> + cisplatin 75 mg/m<sup>2</sup> M, months.  
QOL, quality of life.

## CONCLUSION

The RDs for the Pem/Cis combination are pemtrexed 500 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup>, which is the same regimen used in worldwide for patients with MPM. The combination shows promising efficacy with an acceptable safety profile in Japanese patients with MPM.

On January 2007, Pem/Cis combination therapy was approved and launched for the treatment of patients with MPM in Japan. Intensive post-marketing surveillance in patients with MPM is ongoing.

## Funding

This study has been supported and funded by Eli Lilly Japan K.K., Kobe, Japan.

## Conflict of interest statement

S.A. and Y.N. are employed by the sponsor, Eli Lilly Japan K.K.; N.S. and M.F. are paid consultants to the sponsor.

**Table 4.** Summary of treatment-emergent adverse events (TEAEs) reported >25% patients

System organ class preferred term	Step 1 Level -1 (n = 6)	Level 1 (n = 19)	All treated (n = 25)
<b>Patients with ≥1 TEAEs</b>			
	6	19	25
<b>Laboratory</b>			
Hemoglobin decreased	6	18	24
Red blood cell count decreased	6	16	22
Neutrophil count decreased	5	16	21
White blood cell count decreased	5	15	20
Lymphocyte count decreased	5	12	17
Blood urea increased	5	11	16
Weight decreased	3	12	15
Blood albumin decreased	2	10	12
Platelet count decreased	4	8	12
Protein total decreased	3	9	12
Blood creatinine increased	4	7	11
Neutrophil count increased	2	8	10
White blood cell count increased	2	8	10
Blood sodium decreased	2	7	9
Alanine aminotransferase increased	1	7	8
Protein urine present	1	7	8
Aspartate aminotransferase increased	1	6	7
Blood magnesium decreased	2	5	7
Blood potassium decreased	0	7	7
<b>Non-laboratory</b>			
Nausea	6	18	24
Anorexia	6	16	22
Vomiting	3	15	18
Malaise	5	10	15
Constipation	3	9	12
Hiccups	3	5	8
Rash	2	6	8
Diarrhoea	1	6	7
Oedema	2	5	7
Pyrexia	2	5	7
Dysgeusia	3	4	7
Headache	1	6	7

Level 1: pemtrexed 500 mg/m<sup>2</sup> + cisplatin 75 mg/m<sup>2</sup>  
Level -1: pemtrexed 500 mg/m<sup>2</sup> + cisplatin 60 mg/m<sup>2</sup>  
MedDRA Ver 9.0.

## References

- British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. *Thorax* 2001;56: 250-65.
- Carter SK. Study design principles in the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In: Staquet MJ, editor. *The Design of Clinical Trials in Cancer Therapy*. Brussels, Belgium: Futara Pub Co 1973;242-89.

3. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. *Lung Cancer* 1995;12:199-220.
4. Eguchi K, Kurihara M, Shimosuma K, Hotta T, Murakami M, Suzuki N, et al. Quality of life questionnaire for cancer patients treated with anticancer drugs. *Nippon Ganchiryō Gakkaishi* 1993;28:1140-4 (in Japanese).
5. Green S, Weiss GR. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. *Invest New Drugs* 1992;10:239-53.
6. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. *Oncologist* 2001;6:363-73.
7. Nakagawa K, Kudoh S, Matsui K, Negoro S, Yamamoto N, Latz JE, et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B<sub>12</sub> in Japanese patients with solid tumors. *Br J Cancer* 2006;95:677-782.
8. Pass HI, Hahn SM, Vogelzang NJ, Carbone M. Benign and malignant mesothelioma-Chapter 36. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors *Cancer Principles and Practice of Oncology*. 7th edn. Philadelphia: Lippincott Williams & Wilkins 2004:1687-715.
9. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. *Br J Cancer* 1999;79:666-72.
10. Saijo N and Study Group. Guideline for phase I/II study on anticancer drugs (Draft version). *Med Front (Saishin Igaku)* 2001;56:1515-41 (in Japanese).
11. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). *Adv Enzyme Regul* 1998;38:135-52.
12. Taylor EC, Patel HH. Synthesis of pyrazolo[3,4-d]pyrimidine analogues of the potent antitumor agent N-[4-[2-(2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid (LY231514). *Tetrahedron* 1992;48:8089-100.
13. The International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. *Chest* 1995;108:1122-8.
14. The Japanese Respiratory Society. In: *Clinical Pulmonary Functions Committee, editor. Guideline of Pulmonary Function Test*. Tokyo: Medical Review 2004 (in Japanese).
15. Van Meerbeek JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005;23:6881-9.
16. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003;21:2636-44.

## Minireview

# Emerging ethnic differences in lung cancer therapy

I Sekine<sup>\*1</sup>, N Yamamoto<sup>1</sup>, K Nishio<sup>2</sup> and N Saijo<sup>3</sup>

<sup>1</sup>Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan; <sup>2</sup>Department of Genome Biology, Kinki University School of Medicine, Sayama 589-8511, Japan; <sup>3</sup>Division of Internal Medicine, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa 277-8577, Japan

Although global clinical trials for lung cancer can enable the development of new agents efficiently, whether the results of clinical trials performed in one population can be fully extrapolated to another population remains questionable. A comparison of phase III trials for the same drug combinations against lung cancer in different countries shows a great diversity in haematological toxicity. One possible reason for this diversity may be that different ethnic populations may have different physiological capacities for white blood cell production and maturation. In addition, polymorphisms in the promoter and coding regions of drug-metabolising enzymes (e.g. CYP3A4 and UGT1A1) or in transporters (e.g. ABCB1) may vary among different ethnic populations. For example, epidermal growth factor receptor (EGFR) inhibitors are more effective in Asian patients than in patients of other ethnicities, a characteristic that parallels the incidence of EGFR-activating mutations. Interstitial lung disease associated with the administration of gefitinib is also more common among Japanese patients than among patients of other ethnicities. Although research into these differences has just begun, these studies suggest that possible pharmacogenomic and tumour genetic differences associated with individual responses to anticancer agents should be carefully considered when conducting global clinical trials.

British Journal of Cancer (2008) 99, 1757–1762. doi:10.1038/sj.bjc.6604721 www.bjancer.com

Published online 4 November 2008

© 2008 Cancer Research UK

**Keywords:** lung cancer; ethnicity; epidermal growth factor receptor; pharmacogenomic

Lung cancer is the most common malignancy worldwide. Approximately 1.2 million people are diagnosed with lung cancer annually (accounting for 12.3% of all cancers); the second most common malignancy is breast cancer (10.4%), followed by colorectal cancer (9.4%). As lung cancer almost invariably has a poor prognosis, it is the largest single cause of death from cancer in the world, with a mortality of 1.1 million annually (Stewart and Kleihues, 2003). Only 15% of lung cancer patients have a disease that is confined to the lung and are candidates for surgical resection; most patients with this disease have distant metastases or pleural effusion at the time of their initial diagnosis. These patients can be treated with systemic chemotherapy, but the efficacy of currently available anticancer agents is limited and patients with advanced diseases rarely live long.

As the development of new anticancer agents and chemotherapeutic regimens is both time and money consuming, clinical trials need to be as efficient as possible. One effort in this direction has been the adoption of global clinical trials for new agents that involve trial centres on more than one continent; this strategy enables adequate sample sizes to be obtained in a relatively short-time period and eliminates the need for redundant clinical trials with similar objectives conducted in different countries. However, whether the results of clinical trials performed in one population can be fully extrapolated to other populations remains questionable because of potential differences in trial designs, study-specific criteria, patient demographics, frequency of monitoring, and population-related

pharmacokinetics, pharmacodynamics and pharmacogenomics. Recently, these genetic and physiologic factors influencing cancer chemotherapy have been increasingly examined and reported.

## CLINICAL OBSERVATIONS OF TOXICITY DURING CYTOTOXIC CHEMOTHERAPY

A comparison of phase III trials for the same drug combinations against non-small cell lung cancer conducted in different countries shows a great diversity in toxicity (Sekine *et al.*, 2006). Among trials studying the combination of carboplatin and paclitaxel, the dose of carboplatin was fixed in all the trials, but the dose of paclitaxel was 200 mg m<sup>-2</sup> in Japanese and European trials and 225 mg m<sup>-2</sup> in American trials. Grades 3–4 neutropenia was noted in 88% of the patients in the Japanese trial, 15–51% of the patients in the European trials, and 6–65% of the patients in the American trials. Meanwhile, grades 3–4 febrile neutropenia was encountered in 16% of the patients in the Japanese trial, 0–9% of the patients in the European trials, and 2–4% of the patients in the American trials (Table 1). For combinations of cisplatin and docetaxel (Table 1) and cisplatin and vinorelbine (Table 2), the incidences of grades 3–4 neutropenia and febrile neutropenia were almost the same between phase III trials performed in different areas, but the doses of docetaxel and vinorelbine in the Japanese trials were lower than those in the European and American trials. Thus, neutropenia in patients receiving a combination of platinum and antimicrotubule agents may be more severe in Japanese than in Europeans and Americans. A higher frequency of grades 3–4 neutropenia in Japanese patients than in American patients was associated with combinations of cisplatin and irinotecan (65 vs

\*Correspondence: Dr I Sekine; E-mail: isekine@ncc.go.jp  
Revised 9 September 2008; accepted 18 September 2008; published online 4 November 2008

**Table 1** Toxicity associated with a combination of platinum and taxane

Research group	Chemotherapy dose		No. of patients	Grades 3-4 toxicity (%)		
	Platinum	Taxane		NP	FNP	Reference
<i>A combination of carboplatin and paclitaxel</i>						
Japan	6 (AUC)	200 (mg m <sup>-2</sup> )	145	88	16	Ohe et al (2007)
Greece	6 (AUC)	200 (mg m <sup>-2</sup> )	252	15	0	Kosmidis et al (2002)
EU	6 (AUC)	200 (mg m <sup>-2</sup> )	309	51	4	Roselli et al (2002)
ECOG	6 (AUC)	225 (mg m <sup>-2</sup> )	290	63	4	Schiller et al (2002)
SWOG	6 (AUC)	225 (mg m <sup>-2</sup> )	206	57	2	Kelly et al (2001)
SWOG	6 (AUC)	225 (mg m <sup>-2</sup> )	182	—	3	Gandara et al (2004)
USA	6 (AUC)	225 (mg m <sup>-2</sup> )	190	65	—	Belani et al (2005)
USA	6 (AUC)	225 (mg m <sup>-2</sup> )	345	6	—	Herbst et al (2004)
<i>A combination of cisplatin and docetaxel</i>						
Japan	80 (mg m <sup>-2</sup> )	60 (mg m <sup>-2</sup> )	151	74	2	Ohe et al (2007)
ECOG	75 (mg m <sup>-2</sup> )	75 (mg m <sup>-2</sup> )	289	69	11	Schiller et al (2002)
USA	75 (mg m <sup>-2</sup> )	75 (mg m <sup>-2</sup> )	408	75	5	Fossella et al (2003)

NP, neutropenia; FNP, febrile neutropenia.

**Table 2** Toxicity associated with a combination of cisplatin and vinorelbine

Research group	Chemotherapy dose (mg m <sup>-2</sup> )		No. of patients	Grades 3-4 toxicity (%)		
	Cisplatin	Vinorelbine		NP	FNP	Reference
Japan	80 (day 1)	25 (days 1, 8)	145	88	18	Ohe et al (2007)
Greece	80 (day 8)	30 (days 1, 8)	204	37	11	Georgoulis et al (2005)
France	100 (day 1)	30 (weekly)	156	83	22	Pujol et al (2005)
EU	120 (day 1)	30 (weekly)	206	79	4	Le Chevalier et al (1994)
SWOG	100 (day 1)	25 (weekly)	202	76	1	Kelly et al (2001)
USA	100 (day 1)	25 (weekly)	404	79	5	Fossella et al (2003)

NP, neutropenia; FNP, febrile neutropenia.

32%,  $P < 0.001$ ) and cisplatin and etoposide (92 vs 66%,  $P < 0.001$ ) for the treatment of extensive small-cell lung cancer (Lara et al, 2007).

How can this ethnic difference in the severity of neutropenia be explained? One possibility is that the physiological capacity of the white blood cell production and maturation may vary among different ethnic populations. An asymptomatic reduction in neutrophils (benign neutropenia) is more commonly observed in individuals of African descent than in Caucasians, and no data on this phenomenon are available for Asians (Hsieh et al, 2007). The mechanisms are unclear, but a lower bone marrow reserve, an intrinsic marrow difference, an abnormal cytokine response, or any combination of these factors have been suggested (Hsieh et al, 2007). The lower neutrophil counts were associated with higher levels of IL-8 and granulocyte colony-stimulating factor in African volunteers. Thus, these cytokines are considered to compensate for the relatively low neutrophil counts in this population (Mayr et al, 2007). A recent report showed that ethnicity-related low neutrophil counts were associated with neutrophil elastase (ELA2) polymorphisms (C-199A), but not with serum cytokine levels (Grann et al, 2007).

#### ETHNIC DIFFERENCES IN DRUG METABOLISING ENZYMES

An explanation for the ethnic differences in haematological toxicity may be the varying activities of drug-metabolising enzymes and transporters that are mainly associated with polymorphisms in the promoter and coding regions of these enzymes (Fujita and Sasaki, 2007). The haematological toxicity of

docetaxel monotherapy was associated with the clearance of this agent in Asian patients, a phenomenon that can be largely explained by CYP3A4 activity (Yamamoto et al, 2000). A study conducted in the Netherlands showed that docetaxel clearance was associated with the homozygous C1236T polymorphism in the ABCB1 (p-glycoprotein) gene (ABCB1\*8) but was not associated with any CYP3A4 gene polymorphisms (Bosch et al, 2006). In contrast, docetaxel pharmacokinetics were not associated with the percent decrease in neutrophil counts nor with any polymorphisms in the CYP3A4 and ABCB1 genes in American patients (Lewis et al, 2007). Another example of ethnic differences in drug-metabolising enzymes is the association between polymorphisms in genes involved in irinotecan metabolism and irinotecan-induced neutropenia. Among the patients who received irinotecan with or without another anticancer agent, grade 4 neutropenia was noted in 40–57% of the patients with UDP-glucuronosyltransferase (UGT) 1A1\*28 (a polymorphism in the promoter region of the UGT1A1 gene) homozygosity, whereas neutropenia was only observed in 15% or less of the patients with wild-type alleles. This association was consistent in both Asian and Caucasian patients, although the frequency of homozygosity was about 10% in Caucasians and much lower in Asians. The UGT1A1\*6 allele is another polymorphism at exon 1 that is associated with defective glucuronidating function and is found almost exclusively in Asian individuals with a frequency as high as 20% (Fujita and Sasaki, 2007). UGT1A1\*6 is significantly linked to polymorphisms of UGT1A7 and UGT1A9. A haplotype including UGT1A1\*6 and UGT1A7\*3, noted in as many as 15% of Japanese patients, and UGT1A1\*6 homozygosity, noted in 7% of Korean patients, were significantly associated with decreased glucuronosyltransferase activity for SN-38 and severe neutropenia (Han et al, 2006; Fujita

et al, 2007). In 177 Japanese patients treated with irinotecan including chemotherapy, a homozygous or double heterozygous genotype for UGT1A1\*6 and UGT1A1\*28 (\*6/\*6, \*28/\*28 or \*6/\*28) was significantly associated with severe neutropenia (Minami et al, 2007). In addition, patients with a homozygous C3435T polymorphism in the ABCB1 gene are four-fold more likely to develop grade 3 diarrhoea when treated with a combination of cisplatin and irinotecan (Lara et al, 2007).

Data on associations between polymorphisms in genes coding drug-metabolising enzymes and therapeutic efficacy remain scarce. A recent prospective study in 250 patients with metastatic colorectal cancer showed a significantly higher response rate (67 vs 40%) and a nonsignificant survival advantage (hazard ratio (HR): 0.81; 95% confidence interval (CI): 0.45–1.44) in patients homozygous for UGT1A1\*28, compared with those with wild-type alleles; these outcomes were associated with a higher exposure to SN-38 (Toffoli et al, 2006). In a study of 81 NSCLC patients, those who were homozygous for UGT1A1\*6 had a lower response rate (0 vs 50%,  $P=0.038$ ) and a poorer MST (7.6 vs 17.7 months,  $P=0.017$ ) as well as greater toxicities than the other patients (Han et al, 2006). The most plausible explanation for the negative effects of UGT1A1\*6 on treatment outcome may be that the dose intensity or cycle number might have been reduced in patients with UGT1A1\*6 because of polymorphism-associated toxicities (Fujita and Sasaki, 2007).

These pharmacogenetic analyses have been rather preliminary. Data on genotyping, pharmacokinetics, and pharmacodynamics collected from a large number of patients with different ethnic backgrounds are needed to demonstrate the cause of ethnic differences in chemotherapy-associated toxicity.

## EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS

Epidermal growth factor receptor (EGFR), a cell membrane receptor with tyrosine kinase activity, is expressed in most patients with NSCLC and plays a role in cellular proliferation, inhibition of apoptosis, angiogenesis, metastatic potential, and chemoresistance. Small-molecule inhibitors of EGFR, such as gefitinib and erlotinib, have shown antitumor activity and have alleviated symptoms in NSCLC patients who were previously treated with standard chemotherapy. Two randomized phase II studies, IDEAL (Iressa Dose Evaluation in Advanced Lung Cancer)-1 (involving 210 patients and conducted in Europe, Australia, South Africa, and Japan) and IDEAL-2 (involving 216 patients and conducted in the USA), have evaluated the efficacy of gefitinib at a dose of either 250 mg daily or 500 mg daily in patients with advanced NSCLC in whom earlier platinum-based chemotherapy had failed. No difference in the response rates between the doses was noted, but an increased response rate was recorded for never smokers, women, and those with an adenocarcinoma histology, compared with patients who did not have these characteristics. In addition, the response rate was 28% in Japanese patients but only 9–12% in patients of other ethnicities (Fukuoka et al, 2003; Kris et al, 2003). A randomized phase III trial, ISEL (Iressa Survival Evaluation in Lung Cancer), of gefitinib vs a placebo in 1692 NSCLC patients who had been previously treated with one or two chemotherapeutic regimens failed to show any survival benefit of gefitinib; in the overall population, the median survival times (MSTs) in the gefitinib and placebo arms were 5.6 and 5.1 months, respectively (HR: 0.89; 95% CI: 0.78–1.03). A subgroup analysis, however, showed that the MST was longer in Asian patients receiving gefitinib than in those receiving the placebo (MST: 9.5 vs 5.5 months; HR: 0.66; 95% CI: 0.48–0.91). Similar results were seen for never smokers: patients receiving gefitinib survived longer than those receiving the placebo (MST: 8.9 vs 6.1 months; HR: 0.67, 95% CI: 0.49–0.91) (Thatcher et al, 2005).

A similar association between objective responses and ethnicity was observed in studies on erlotinib monotherapy for previously treated advanced NSCLC. In an American phase II trial of this agent in 57 advanced NSCLC patients with disease progression or relapse after platinum-based chemotherapy, the response rate was 12% and the MST was 8.4 months (Perez-Soler et al, 2004). In contrast, the combined data of two Japanese phase II trials of erlotinib in similar patient populations showed objective responses in 30 of 106 (28%) patients and an MST of 13.8 months. Among the responders, significantly higher proportions of females (50%) than males (17%) ( $P=0.0009$ ) and of never smokers (51%) than smokers (14%) were observed ( $P<0.0001$ ) (Tamura et al, 2007). A phase III trial of erlotinib or a placebo in 731 NSCLC patients previously treated with one or two chemotherapy regimens showed that the response rate in Asian patients was higher than that in patients of other ethnicities (28 vs 10%,  $P=0.02$ ) (Shepherd et al, 2005).

These results of phases II and III trials consistently suggest that EGFR tyrosine kinase inhibitors may be more effective in Asian patients than in patients of other ethnicities.

In April 2004, the activating mutations of the EGFR gene were identified in NSCLC specimens, and cancers with these mutations were reported to be highly sensitive to gefitinib. The populations with higher responses to gefitinib (females, non-smokers and patients with an adenocarcinoma histology) also have higher incidences of EGFR mutations (Kosaka et al, 2004; Pao et al, 2004; Shigematsu et al, 2005). The incidence of EGFR mutations in surgically resected tissue samples is summarised in Table 3 (Kosaka et al, 2004; Pao et al, 2004; Marchetti et al, 2005; Qin et al, 2005; Shigematsu et al, 2005; Soung et al, 2005; Tokumo et al, 2005; Yang et al, 2005; Sasaki et al, 2006). The incidence varies from one report to another, but EGFR mutations tend to be more common among patients with an adenocarcinoma histology and among non-smokers. Among Asian patients, the average incidences of EGFR mutations were 31% overall, 47% among patients with adenocarcinoma, and 56% among non-smokers; among other ethnic populations, however, the average incidences were 7–8% overall, 13–15% among patients with adenocarcinoma, and 34–35% among non-smokers (Table 3). Thus, the percentage of responders to gefitinib or erlotinib almost paralleled the percentage of patients with EGFR mutations.

The mechanism responsible for the high frequency of EGFR mutations in Asian patients is a subject of great interest, and polymorphisms in the regulatory sequence of the EGFR gene have been vigorously investigated. The CA simple sequence repeat 1 (CA-SSR1), a highly polymorphic locus containing 14–21 CA dinucleotide repeats, is located at the 5' end of intron 1 of the EGFR gene. Studies of CA-SSR1 repeat length and EGFR expression in breast cancer tissues have shown a constant decline in EGFR expression with increasing repeat length (Buerger et al, 2000, 2004). In addition, a shorter repeat length was associated with an elevated risk of lung cancer (Zhang et al, 2007) and poor survival in NSCLC patients (Dubey et al, 2006). The CA-SSR1 repeat length distribution varies according to ethnicity, with Asians tending to have longer repeats than Americans (Liu et al, 2003). Two single-nucleotide polymorphisms in the promoter region of the EGFR gene (–219G/T and –191C/A) were also associated with promoter activity and EGFR expression (Liu et al, 2005), and their polymorphic types (associated with low EGFR expression) were more common among Asians than among other ethnicities (Nomura et al, 2007). These observations suggest that many Asians have polymorphic types that lead to a decreased intrinsic production of EGFR protein. If a certain critical level of EGFR is required to drive the cell toward a malignant phenotype, another mechanism including activating mutations of EGFR and/or the autonomous activation of downstream signalling may be required for the development of lung cancer among Asians (Nomura et al, 2007).

**Table 3** Incidence of EGFR mutations in surgically resected specimens

Author	Country	All cases		Adenocarcinoma		Non-smokers	
		Total N	Mutation N (%)	Total N	Mutation N (%)	Total N	Mutation N (%)
<i>Western areas</i>							
Shigematsu	USA	80	11 (14)	44	11 (25)	26	7 (27)
Pao	USA	96	11 (11)	72	11 (15)	15	7 (47)
Yang	USA	219	26 (12)	164	25 (15)	34	12 (35)
Marchetti	Italy	860	39 (5)	375	39 (10)	103*	23 (22)
	Subtotal	1255	87 (7)	655	86 (13)	75	26 (35)
<i>Asian areas</i>							
Shigematsu	Japan	263	71 (27)	154	67 (44)	78	47 (60)
Kosaka	Japan	277	111 (40)	224	110 (49)	112*	76 (68)
Tokumo	Japan	120	38 (32)	82	37 (45)	36	25 (69)
Sasaki	Japan	95	35 (37)	71	32 (45)	36	25 (69)
Shigematsu	Taiwan	93	32 (34)	55	31 (56)	55	27 (49)
Qin	China	41	10 (24)	17	7 (41)	21	6 (29)
Soung	Korea	153	30 (20)	69	26 (38)	54	25 (46)
Shigematsu	Others	361	107 (30)	214	102 (48)	135	76 (56)
	Subtotal	1403	434 (31)	886	412 (47)	415	231 (56)
<i>Other areas</i>							
Shigematsu	Australia	83	6 (7)	36	5 (14)	7	4 (57)
Shigematsu	Others	158	13 (8)	75	12 (16)	31	9 (29)
	Subtotal	241	19 (8)	111	17 (15)	38	13 (34)
	Total	2899	540 (19)	1652	515 (31)	528	270 (51)

\*Including only patients with adenocarcinoma histology.

### INTERSTITIAL LUNG DISEASE ASSOCIATED WITH GEFITINIB AND ERLOTINIB

The frequencies of grades 3–4 common toxicities after the administration of gefitinib, including diarrhoea, skin rash, and elevated liver transaminase levels, have been similar among study populations, but the incidence of severe interstitial lung disease (ILD) associated with the administration of gefitinib differs between patients in Japan and those in other countries. In the IDEAL studies, two Japanese patients developed grades 3–4 ILD (2%), whereas no patients outside of Japan experienced ILD (Fukuoka *et al*, 2003; Kris *et al*, 2003). A retrospective study of 1976 consecutive patients treated with gefitinib at 84 institutions showed that the incidence of ILD was 3.5% and the mortality rate was 1.6%. Several risk factors for the development of gefitinib-induced ILD were identified in the Japanese population: a history of pulmonary fibrosis, a history of smoking, a poor performance status, and a male sex (Ando *et al*, 2006). A similar incidence of ILD (4.6%) was also noted in association with erlotinib chemotherapy in Japanese phase II trials (Tamura *et al*, 2007).

The association between ILD and anticancer treatment is a major topic in Japan because (1) the diagnosis of ILD can be difficult and a consensus among physicians is sometimes not reached, (2) the risk factors for ILD have not been fully

established, (3) an effective treatment for ILD has not been established and the condition is often fatal, and (4) the low frequency of this complication makes it difficult to conduct pertinent clinical trials. Gefitinib-induced ILD seems to be more common among Japanese patients than among other patients, but the reasons for this ethnic difference are totally unknown.

### CONCLUSION

The findings discussed here suggest that considerable variations in the toxicity and efficacy of anticancer agents may exist among patients of different ethnicities. Although research into these differences has just begun, these studies suggest that possible pharmacogenomic and tumour genetic differences associated with individual responses to anticancer agents should be carefully considered when conducting global clinical trials.

### ACKNOWLEDGEMENTS

We thank Mika Nagai for her invaluable assistance in the preparation of this manuscript.

### REFERENCES

- Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. *J Clin Oncol* 24: 2549–2556
- Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilienbaum R, Natale RB (2005) Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. *Ann Oncol* 16: 1069–1075

- Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH (2006) Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. *Clin Cancer Res* 12: 5786–5793
- Buerger H, Gebhardt F, Schmidt H, Beckmann A, Huttmacher K, Simon R, Lelle R, Boecker W, Brandt B (2004) Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence – first results of an inter-ethnic breast cancer study. *J Pathol* 203: 545–550
- Dubey S, Stephenson P, Levy DE, Miller JA, Keller SM, Schiller JH, Johnson DH, Kolesar JM (2006) EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. *J Thorac Oncol* 1: 406–412
- Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 21: 3016–3024
- Fujita K, Ando Y, Nagashima F, Yamamoto W, Eodo H, Araki K, Kodama K, Miya T, Narabayashi M, Sasaki Y (2007) Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1\*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. *Cancer Chemother Pharmacol* 60: 515–522
- Fujita K, Sasaki Y (2007) Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. *Curr Drug Metab* 8: 554–562
- Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Basega J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol* 21: 2237–2246
- Gandara DR, Ohe Y, Kubota K, Nishiwaki Y, Ariyoshi Y, Saijo N, Williamson S, Lara PN, Crowley J, Fukuoka M (2004) Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials. *Proc ASCO* 22: 618s
- Georgoulas V, Ardanavis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidakis D (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. *J Clin Oncol* 23: 2937–2945
- Grann V, Bowman N, Wei Y, Horowitz M, Joseph C, Abdul K, Abdul K, Barlatier H, Sandoval R, Jacobson J, Hershman D (2007) Ethnic neutropenia among women of European, African, and Caribbean backgrounds. *J Clin Oncol* 25(Suppl): 343s (abstract 6587)
- Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jiang J, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. *J Clin Oncol* 24: 2237–2244
- Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Olliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. *J Clin Oncol* 22: 785–794
- Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP (2007) Prevalence of neutropenia in the US population: age, sex, smoking status, and ethnic differences. *Ann Intern Med* 146: 486–492
- Kelly K, Crowley J, Bunn Jr PA, Presant CA, Greystad PK, Moynour GM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. *J Clin Oncol* 19: 3210–3218
- Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer Res* 64: 8919–8923
- Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. *J Clin Oncol* 20: 3578–3585
- Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 290: 2149–2158
- Lara P, Redman M, Lenz H, Gordon M, Shibata T, Fukuda H, Tamura T, Saijo N, Natale R, Gandara D (2007) Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. *J Clin Oncol* 25(Suppl): 390s (abstract 7524)
- Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffe P, Panizo A, Gaspard MH, Ravaoli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. *J Clin Oncol* 12: 360–367
- Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ (2007) A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. *Clin Cancer Res* 13: 3302–3311
- Liu W, Innocenti F, Chen P, Das S, Cook Jr EH, Ratain MJ (2003) Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. *Clin Cancer Res* 9: 1009–1012
- Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook Jr EH, Ratain MJ (2005) A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. *Cancer Res* 65: 46–53
- Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Campese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. *J Clin Oncol* 23: 857–865
- Mayr FB, Spiel AO, Leitner JM, Firbas C, Kliegel T, Jilma B (2007) Ethnic differences in plasma levels of interleukin-8 (IL-8) and granulocyte colony stimulating factor (G-CSF). *Transl Res* 149: 10–14
- Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1\*6 and \*28. *Pharmacogenomics* 17: 497–504
- Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF (2007) Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. *PLoS Med* 4: e125
- Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol* 18: 317–323
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci USA* 101: 13306–13311
- Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. *J Clin Oncol* 22: 3238–3247

- Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morere JF, Milleron B, Debieuvre D, Castera D, Souquet PJ, Moro-Sibilot D, Lemarie E, Kessler R, Janicot H, Braun D, Spaeth D, Quantin X, Clary C (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. *Ann Oncol* 16: 602-610
- Qin BM, Chen X, Zhu JD, Pei DQ (2005) Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. *Cell Res* 15: 212-217
- Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. *Ann Oncol* 13: 1539-1549
- Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H, Matsumura A, Iuchi K, Haneda H, Suzuki E, Kobayashi Y, Yano M, Fujii Y (2006) EGFR and erbB2 mutation status in Japanese lung cancer patients. *Int J Cancer* 118: 180-184
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 346: 92-98
- Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Saijo N, Tamura T (2006) Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. *Lung Cancer* 53: 157-164
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maolekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 353: 123-132
- Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 97: 339-346
- Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, Yoo NJ, Lee SH (2005) Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. *Virchows Arch* 446: 483-488
- Stewart B, Kleihues P (2003) The global burden of cancer. In *World Cancer Report. International Agency for Research on Cancer*, Stewart B, Kleihues P (eds), pp 11-19. IARC Press: Lyon
- Tamura T, Nishiwaki Y, Watanabe K, Nakagawa K, Matsui K, Takahashi T, Segawa Y, Ichinose Y, Fukuoka M, Saijo N (2007) Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non-small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies. *J Thorac Oncol* 2(Suppl): s742
- Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* 366: 1527-1537
- Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Bion P, Frustaci S (2006) The role of UGT1A1\*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. *J Clin Oncol* 24: 3061-3068
- Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF, Shimizu N (2005) The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. *Clin Cancer Res* 11: 1167-1173
- Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N (2000) Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. *J Clin Oncol* 18: 2301-2308
- Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, Meerzaman D, Hong KM, Mann F, Dracheva T, Fukuoka J, Travis W, Caporaso NE, Harris CC, Jen J (2005) Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. *Clin Cancer Res* 11: 2106-2110
- Zhang W, Weissfeld JL, Romkes M, Land SR, Grandis JR, Siegfried JM (2007) Association of the EGFR intron 1 CA repeat length with lung cancer risk. *Mol Carcinog* 46: 372-380